John J. Tentler

4.3k total citations · 1 hit paper
79 papers, 3.1k citations indexed

About

John J. Tentler is a scholar working on Oncology, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, John J. Tentler has authored 79 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 35 papers in Molecular Biology and 18 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in John J. Tentler's work include Growth Hormone and Insulin-like Growth Factors (16 papers), Cancer-related Molecular Pathways (13 papers) and Hypothalamic control of reproductive hormones (13 papers). John J. Tentler is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (16 papers), Cancer-related Molecular Pathways (13 papers) and Hypothalamic control of reproductive hormones (13 papers). John J. Tentler collaborates with scholars based in United States, Canada and United Kingdom. John J. Tentler's co-authors include Todd M. Pitts, Aik Choon Tan, Sabine Eckhardt, Stephen Leong, Wells A. Messersmith, John J. Arcaroli, Colin D. Weekes, Antonio Jimeno, Mark R. Kelley and Nicholas Emanuele and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

John J. Tentler

77 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Patient-derived tumour xenografts as models for oncology drug development

2012 933 citations John J. Tentler, Aik Choon Tan et al. profile →

Peers

Countries citing papers authored by John J. Tentler

Since Specialization

Citations

This map shows the geographic impact of John J. Tentler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J. Tentler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J. Tentler more than expected).

Fields of papers citing papers by John J. Tentler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John J. Tentler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J. Tentler. The network helps show where John J. Tentler may publish in the future.

Co-authorship network of co-authors of John J. Tentler

This figure shows the co-authorship network connecting the top 25 collaborators of John J. Tentler. A scholar is included among the top collaborators of John J. Tentler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John J. Tentler. John J. Tentler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors	Molecular Cancer Therapeutics	Jennifer R. Diamond, Todd M. Pitts et al.	10
2	RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer	BMC Cancer	John J. Tentler, Julie Lang et al.	21
3	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer	Molecular Cancer Therapeutics	Anna Capasso, Stacey M. Bagby et al.	27
4	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma	Molecular Cancer Therapeutics	Katherine A. Minson, John J. Tentler et al.	26
5	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)	Investigational New Drugs	Kit Man Wong, Heather M. Selby et al.	16
6	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer	Molecular Cancer Therapeutics	John J. Tentler, Aik Choon Tan et al.	39
7	Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants	Molecular Cancer Therapeutics	John J. Tentler, Aik Choon Tan et al.	21
8	Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer	Clinical Cancer Research	Anna Spreafico, John J. Tentler et al.	58
9	Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models	Clinical Cancer Research	Todd M. Pitts, Gillian N. Kulikowski et al.	46
10	CtBP1 Is Expressed in Melanoma and Represses the Transcription of p16INK4a and Brca1	Journal of Investigative Dermatology	Hui Deng, Jing Liu et al.	28
11	Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models	Clinical Cancer Research	Jennifer R. Diamond, S. Gail Eckhardt et al.	39
12	Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development	Clinical Cancer Research	Todd M. Pitts, Aik Choon Tan et al.	56
13	Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- ras –Mutated Colorectal Cancer	Molecular Cancer Therapeutics	John J. Tentler, Sujatha Nallapareddy et al.	63
14	The Epithelial-Specific ETS Transcription Factor ESX/ESE-1/Elf-3 Modulates Breast Cancer-Associated Gene Expression	DNA and Cell Biology	John J. Tentler, Scott E. Diamond et al.	43
15	Ethanol, growth hormone and testosterone in peripubertal rats	Journal of Endocrinology	John J. Tentler, Nancy LaPaglia et al.	38
16	Coupled reverse transcription-polymerase chain reaction (RT-PCR) technique is comparative, quantitative, and rapid: Uses in alcohol research involving low abundance mRNA species such as hypothalamic LHRH and GRF	Alcohol	Mark R. Kelley, John J. Tentler et al.	50
17	In vivo effects of acute EtOH on rat α and β luteinizing hormone gene expression	Alcohol	Mary Ann Emanuele, John J. Tentler et al.	28
18	The Effect of in Vitro Ethanol Exposure on Lhrh Release from Perifused Rat Hypothalami	Endocrine Research	Mary Ann Emanuele, John J. Tentler et al.	15
19	In Vitro Effect of Ethanol Exposure on Basal and GnRH-Stimulated LH Secretion from Pituitary Cells	Endocrine Research	Mary Ann Emanuele, John J. Tentler et al.	13
20	Extrahypothalamic brain prolactin: characterization and evidence for independence from pituitary prolactin	Brain Research	Nicholas Emanuele, John J. Tentler et al.	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact